RPHM: שווי שוק לרווח נקי מותאם קצב צמיחה reneopharma.com
Reneo Pharmaceuticals develops drugs for rare pathologies, with its financial stability tied to test results. The growth-adjusted valuation ratio provided on GURU.Markets shows that the current level is 0.00. The management structure is currently undergoing a stage of systematic merger or liquidation. Meanwhile, developments in the US are protected from external sanctions by the humanitarian status of medicine.
Reneo Pharmaceuticals (RPHM) - פילוחי מדדים ודוחות פיננסיים
The PEG ratio compares the market value of earnings to their growth rate to determine the fairness of a business valuation, where values below one signal that an asset is undervalued relative to its expansion. Analyzing this PEG chart allows for portfolio stress-testing, considering that for Reneo Pharmaceuticals (RPHM), a high growth rate may be constrained by sanction risks within raw material supply chains.
